Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
161 results in PubMed
Peer-reviewed biomedical literature from the US National Library of Medicine, most relevant first. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy.
Cordas Dos Santos DM, Tix T, Shouval R, et al. · Nat Med · 2024Systematic Review, Meta-Analysis
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi NC, Anderson LD, Shah N, et al. · N Engl J Med · 2021Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Berdeja JG, Madduri D, Usmani SZ, et al. · Lancet · 2021Clinical Trial, Phase I, Clinical Trial, Phase II
- Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis.
Liang X, Wang Y, Luo B, et al. · J Immunother Cancer · 2024Meta-Analysis, Comparative Study
- Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.
Tix T, Alhomoud M, Shouval R, et al. · Clin Cancer Res · 2024Systematic Review, Meta-Analysis
- Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel J, Dhakal B, Yong K, et al. · N Engl J Med · 2023Clinical Trial, Phase III, Comparative Study
- Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies.
Touzeau C, Krishnan AY, Moreau P, et al. · Blood · 2024Clinical Trial, Phase II, Clinical Trial, Phase I
- GPRC5D-Targeted CAR T Cells for Myeloma.
Mailankody S, Devlin SM, Landa J, et al. · N Engl J Med · 2022Clinical Trial, Phase I
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. · N Engl J Med · 2023Clinical Trial, Phase III, Comparative Study
- Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma.
Tix T, Alhomoud M, Shouval R, et al. · Mol Ther · 2025Systematic Review, Meta-Analysis
- Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.
Einsele H, San-Miguel J, Dhakal B, et al. · Lancet Oncol · 2026Multicenter Study, Randomized Controlled Trial
- A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients.
Martino EA, Caridà G, Lofaro D, et al. · ESMO Open · 2025Network Meta-Analysis, Systematic Review
- In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study.
An N, Wang D, Zhang P, et al. · Nat Med · 2026Clinical Trial, Phase I
- Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.
Zhang C, Wu H, Cao T, et al. · Am J Hematol · 2026Systematic Review, Meta-Analysis
- Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma.
Sidana S, Ahmed N, Akhtar OS, et al. · Blood · 2025Clinical Trial, Phase II, Multicenter Study
- Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial.
Xu J, Wang BY, Yu SH, et al. · J Hematol Oncol · 2024Clinical Trial, Multicenter Study
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.
Raje N, Berdeja J, Lin Y, et al. · N Engl J Med · 2019Clinical Trial, Phase I, Multicenter Study
- Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.
Shi M, Wang J, Huang H, et al. · Nat Commun · 2024Clinical Trial, Phase II, Clinical Trial, Phase I
- Chimeric Antigen Receptor T-Cells (CAR T-Cells) in Hematological Malignancies: A Systematic Review and Meta-Analysis of Proportions From Clinical Trials.
Filippatos C, Kanteli I, Pasipoularidou DG, et al. · Am J Hematol · 2026Systematic Review, Meta-Analysis
- A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H, Li C, Jiang H, et al. · J Hematol Oncol · 2021Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma.
Qiang W, Lu J, Jia Y, et al. · JAMA Oncol · 2024Clinical Trial, Phase I
- Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ, Grimshaw AA, Silberstein J, et al. · Transplant Cell Ther · 2022Systematic Review, Research Support, Non-U.S. Gov't
- Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA, Chavez JC, Sehgal AR, et al. · Lancet Oncol · 2022Clinical Trial, Phase II, Multicenter Study
- B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD, Garfall AL, Stadtmauer EA, et al. · J Clin Invest · 2019Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial.
Zhou D, Sun Q, Xia J, et al. · Lancet Haematol · 2024Clinical Trial, Phase I
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.